Matinas raises $3.3M via Series C preferred and warrants; appoints Dr. Robin Smith to board

Matinas BioPharma Holdings, Inc.

Initial closing of $1.65M for 1,650 Series C shares; second $1.65M closing subject to shareholder approval by April 10, 2025.
Series C convertible at $0.586/share; warrants exercisable at $0.6446 for 5 years post-shareholder approval.
Proceeds to reduce operating expenses and explore strategic alternatives for MAT2203 and other options.
Dr. Robin L. Smith appointed to board; Herbert J. Conrad resigns as founding Chairman and retires.
Company required to file resale registration statement by 15th day after 2024 10-K filing.

item 1.01 item 3.02 item 3.03 item 5.02 item 5.03 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robin Smith

Director

MTNB · Matinas BioPharma Holdings, Inc.

Filed: February 13, 2025, 6:59 PM ET

the Board, on the recommendation of its Nominating and Corporate Governance Committee, appointed Robin Smith director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Robin Smith was appointed as Director at Matinas BioPharma Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board, on the recommendation of its Nominating and Corporate Governance Committee, appointed Robin Smith director of the Company.

View on SEC.gov

Matinas BioPharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-006481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.